Genmab A (GMAB) Non-Current Receivables (2023 - 2025)
Historic Non-Current Receivables for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $1.1 billion.
- Genmab A's Non-Current Receivables rose 2047.67% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 2047.67%. This contributed to the annual value of $1.1 billion for FY2025, which is 2047.67% up from last year.
- Per Genmab A's latest filing, its Non-Current Receivables stood at $1.1 billion for Q4 2025, which was up 2047.67% from $1.0 billion recorded in Q3 2025.
- In the past 5 years, Genmab A's Non-Current Receivables registered a high of $1.1 billion during Q4 2025, and its lowest value of -$193.0 million during Q3 2024.
- Its 3-year average for Non-Current Receivables is $470.1 million, with a median of $733.0 million in 2023.
- Data for Genmab A's Non-Current Receivables shows a peak YoY increase of 194871.79% (in 2025) and a maximum YoY decrease of 2047.67% (in 2025) over the last 5 years.
- Over the past 3 years, Genmab A's Non-Current Receivables (Quarter) stood at $733.0 million in 2023, then grew by 25.92% to $923.0 million in 2024, then rose by 20.48% to $1.1 billion in 2025.
- Its Non-Current Receivables stands at $1.1 billion for Q4 2025, versus $1.0 billion for Q3 2025 and -$77.0 million for Q2 2025.